Article

SICS: effective solution to huge cataract problem

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world.

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world, said Dr Satyajit Sinha of the AB Eye Institute, Patma, India.

"India's population has just topped 1 billion. There are 16 million cataract patients, and two million are added every year," said Dr Sinha. "But there are just 16,000 ophthalmologists, with 10,000 operating, which means there is a huge patient load for each doctor. We need a simple and effective way to combat cataract."

In this context, the choice of surgery must be weighed against the pressing need for treatment. Extra capsular cataract extraction (ECCE) has a short learning curve, SICS a longer one, but phaco requires a difficult and lengthy apprenticeship. Complications caused by 'in-training calamities' are worse with phaco, Dr Sinha noted.

SICS has a number of advantages. It means earlier rehab for patients than ECCE. There are no complications with sutures or suture removal. It has advantages over phaco for grade three, four and five cataracts. Patients are happy, too.

"One side of the globe is phaco. But on the other side of the globe, where cost is a big factor, we use SICS," he said. "Now high-quality, low-cost surgical instruments are being made indigenously by Indian companies. You can buy a crescent and keratome for $2. You can perform a SICS surgery and buy the IOL for $20 per patient. Phaco machines, by contrast, are expensive," said Dr Sinha.

As a result, India has the most SICS surgeons in the world, and highest number of SICS training centres.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.